Eisai China, Inc.

Primary Objective To evaluate the pharmacokinetics (PK) of dotinurad after single and multiple oral doses in healthy Chinese male and female subjects.

Primary objective: To compare the efficacy of dotinurad 4 mg and febuxostat 40 mg in Chinese gout subjects in terms of the proportion of subjects achieving serum uric acid (SUA) levels ≤6.0 mg/dL at week 24.

Verify the efficacy and safety of lemborexant in the treatment of Chinese subjects with insomnia. The main purpose is to verify using polysomnography (PSG) that lemborexant 10 mg (LEM10) is superior to placebo (PBO) in terms of objective sleep onset time assessed by persistent sleep latency (LPS) after 1 month of treatment in subjects with insomnia. Other purposes include comparing lemborexant 10 mg (LEM10) with placebo (PBO) in terms of sleep parameters (sleep onset time, sleep efficiency, wake-up time after sleep onset) after 1 month of treatment in subjects with insomnia. At the same time, evaluate the effect of lemborexant on the sleep of subjects with insomnia and its safety.